Exceptional responders with invasive mucinous adenocarcinomas: a phase 2 trial of bortezomib in patients with KRAS G12D-mutant lung cancers

KRAS G12D-mutant/p53-deficient non-small-cell lung cancer (NSCLC) models are dependent on the NF-κB pathway that can be down-regulated by the proteasome inhibitor bortezomib. Two exceptional responders were observed on prior clinical trials of bortezomib, both of whom had KRAS G12D-mutant NSCLC, pro...

Descripción completa

Detalles Bibliográficos
Autores principales: Drilon, Alexander, Schoenfeld, Adam J., Arbour, Kathryn C., Litvak, Anna, Ni, Ai, Montecalvo, Joseph, Yu, Helena A., Panora, Elizabeth, Ahn, Linda, Kennedy, Maureen, Haughney-Siller, Anne, Miller, Vincent, Ginsberg, Michelle, Ladanyi, Marc, Arcila, Maria, Rekhtman, Natasha, Kris, Mark G., Riely, Gregory J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory Press 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6549573/
https://www.ncbi.nlm.nih.gov/pubmed/30936194
http://dx.doi.org/10.1101/mcs.a003665

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6549573/
https://www.ncbi.nlm.nih.gov/pubmed/30936194
http://dx.doi.org/10.1101/mcs.a003665

Ejemplares similares